Group 1 - The Hong Kong stock market opened lower on May 19, with the Hang Seng Index down 0.73% and the Hang Seng Tech Index down 1.58% [1] - The Hong Kong Innovative Drug ETF (159567) rose by 0.58% with a turnover rate of 8.02% and a trading volume exceeding 1.15 billion yuan, indicating active trading [1] - The innovative drug ETF closely tracks the Hong Kong Stock Connect Innovative Drug Index, reflecting the performance characteristics of biotech companies listed in Hong Kong [1] Group 2 - The pharmaceutical sector has shown a strong rebound this year, with several pharmaceutical funds reporting net value increases exceeding 30% [1] - Institutions are focusing on investment opportunities in AI healthcare, brain-computer interfaces, and innovative drugs following a period of deep adjustment in the pharmaceutical sector [1] - Guojin Securities emphasizes that innovative drugs and certain semi-innovative drugs remain key investment areas, with upcoming policy changes and data releases expected to catalyze stock price movements [1] Group 3 - Guoxin Securities highlights the rapid growth phase of the innovative drug sector, driven by commercialization and external licensing, which is accelerating revenue growth and profitability [2] - The traditional Chinese medicine sector faces short-term pressure but retains long-term branding and innovation potential [2] - The medical device sector is under short-term pressure due to slow policy implementation and inventory issues, but there are expectations for recovery driven by improved bidding processes [2]

医药｜盈利能力改善，优选创新龙头 20250509 摘要 • 2024 年生物制药板块收入企稳回升，但利润承压；化学制剂板块降本增 效显著，剔除不可比公司后 A 股营收同比增长 5%，扣非净利润增长 24%，主要受益于创新品种放量和 BD 里程碑收入。 • 创新药企业进入高速发展收获期，样本医院数据显示收入同比增速达 60%，2019-2024 年药品注册证书数量显著增加，头部企业运营效率提 升，Biotech 公司业绩加速放量，规模效应显现，盈利能力改善。 • 2025 年一季度，医药基金及非医药基金对化学制剂及其他生物制剂重仓 显著增加，创新药公司受关注度提升，医药板块整体估值虽有修复，但仍 处于近几年底部，存在投资机会。 • 2025 年一季度，甘李药业胰岛素产品提价，净利润同比增长 100%，通 化东宝降价，净利润下滑 49%，主要受新一轮胰岛素集采续约影响，国产 胰岛素企业报价积极。 • 2025 年一季度，荣昌生物、君实等创新药及生物制剂公司亏损收窄，核 心产品上市加速盈利能力提升，预计未来三年内将呈现良好发展趋势。 Q&A 2024 年和 2025 年一季度医药板块的整体盈利情况如何？ 根据 2 ...